Detailed Narrative
Robust FY26 Financial Performance
Privi Speciality Chemicals delivered a strong financial performance for FY26, with overall income growing 21.73% year-on-year to ₹2,582.92 crore. EBITDA increased by an impressive 40.35% to ₹665.45 crore, leading to an EBITDA margin of 25.76%, a significant expansion from 22.35% in FY25. Profit after tax surged by 75.16% to ₹327.54 crore, reflecting improved operational efficiencies and a favorable product mix. Volume growth contributed 6.5% to the overall income, reaching 42,389 metric tons.
Strategic Transformation and Product Mix Enhancement
The company has strategically transformed into a more resilient and diversified speciality aroma chemicals platform. Management emphasized consistent traction across its core aroma chemicals portfolio and a gradual increase in contribution from downstream and value-added products. This shift is supported by strong R&D and innovation, aiming to navigate external uncertainties with confidence and drive consistent profitable growth.
Aggressive Capacity Expansion and Project Timelines
Privi is actively pursuing capacity expansion, with Phase 1 of its capex program on track for completion by June 30, 2026, which will boost total installed capacity to 54,000 metric tons per annum. Phase 2, focusing on multi-speciality aroma chemicals, is also progressing as planned. The long-term vision includes reaching a total capacity of 72,000 metric tons after all three phases, with a realistic timeline of September 2028.
PRIGIV Joint Venture's Growing Contribution
The joint venture with Givaudan, PRIGIV, achieved profitability for the first time in Q4 FY26. An additional capex of ₹50 crore is being implemented to introduce new products and generate revenue. Management projects PRIGIV's sales to reach ₹130 crore this year, a significant increase from ₹55 crore last year, with an ambitious target of ₹300 crore revenue within the next 3-4 years, which is expected to enhance consolidated margins.
Prudent Capital Structure and Shareholder Returns
The company maintains a prudent capital structure, reporting net debt of ₹876 crore as of March 2026, translating to a net debt to EBITDA ratio of 1.33x and a net debt to equity ratio of 0.62x. Healthy operating cash flows of ₹550 crore ensure comfortable liquidity. In line with its commitment to shareholders, the Board recommended a dividend of ₹10 per share for FY26, representing a 100% payout of the face value, reflecting confidence in future cash flow generation.
Biotech and Backward Integration Initiatives
Privi is investing in complex biotech initiatives, including a demonstration plant with a capex of ₹70-75 crore, to convert waste into higher-value products, differentiating itself from 2G alcohol producers. Commercial production of new molecules like ethyl maltol, maltol, and cyclopentanone is targeted by the end of Q1 next financial year (June 2027). The company also plans backward integration for furfural, aiming for implementation post 2 years (FY28-29).
Raw Material Sourcing and Supply Chain Resilience
To mitigate risks from raw material price volatility and global supply chain disruptions, Privi employs annual contracts for renewable raw materials and six-monthly contracts for non-pinene-based products. The company maintains substantial inventory (3 months stock plus 2-3 months in pipeline) and fosters transparent customer relationships, enabling it to pass on price increases and position itself as a reliable, high-quality partner.